SillaJen Anticancer Drug 'BAL0891' Poster Presentation in Boston, USA

Sillajen announced that the clinical research overview of its anticancer drug 'BAL0891,' currently undergoing Phase 1 clinical trials in South Korea and the United States, has been accepted for poster presentation at the ‘2023 EORTC-NCI-AACR’ symposium to be held on the 11th of next month in Boston, Massachusetts, USA.

[Photo by Shillajen]

The EORTC-NCI-AACR symposium is an international conference jointly organized by the European Organisation for Research and Treatment of Cancer (EORTC), the U.S. National Cancer Institute (NCI), and the American Association for Cancer Research (AACR), held annually on a rotating basis between Europe and the United States. Last year, it was held in Barcelona, Spain.

BAL0891 is an anticancer drug that Sillajen licensed from Swiss company Basilea in September last year. It is a Mitotic Checkpoint Inhibitor that acts as a dual kinase inhibitor by inhibiting two phosphorylation enzymes: Threonine Tyrosine Kinase (TTK) and Polo-like Kinase 1 (PLK1).

BAL0891 is currently in Phase 1 clinical trials. Patient enrollment began in earnest in the United States in February, targeting patients with metastatic solid tumors, and patient enrollment also started domestically in July.

Sillajen expects that this EORTC-NCI-AACR symposium will serve as an opportunity to discuss long-term clinical development plans and clinical strategies. Typically, when an international conference is held, many researchers from the host country attend, so it is anticipated that information about the drug and clinical trials of 'BAL0891' can be effectively communicated to local U.S. researchers.

A Sillajen representative explained the significance of this presentation, stating, “The fact that the clinical research overview of a drug that has just begun clinical trials has been consecutively accepted as presentation material at world-renowned conferences indicates the high value of the drug and great expectations for the research.”

This content was produced with the assistance of AI translation services.